Havrix Junior

Havrix Junior is a pediatric hepatitis A vaccine containing inactivated hepatitis A virus adsorbed on aluminium hydroxide, produced on human diploid cells. It is supplied as an injectable formulation for intramuscular use, marketed in the European Union. The vaccine is prescribed by healthcare professionals to stimulate active immunity against hepatitis A infection. It is intended for children typically aged 12 months to 15 years, following national immunisation schedules.

Havrix Junior is indicated for the prevention of hepatitis A infection in children and adolescents.

- Primary prophylaxis for hepatitis A in children 12 months and older. - Completion of a two‑dose series, spaced 6 to 12 months apart, as recommended by local health authorities. - Use in travelers to regions where hepatitis A is endemic, when administered according to travel schedule. - Administration to individuals with chronic liver disease to reduce risk of severe hepatitis A. - Optional use in outbreak settings to quickly increase community immunity.

The safety profile of Havrix Junior reflects typical vaccine reactions, most of which are mild and transient.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever within 24‑48 hours after vaccination. - Headache or mild fatigue lasting a day or two. - Temporary loss of appetite or mild gastrointestinal upset. - Mild muscle aches or joint stiffness. - Localized bruising or tenderness at the injection site.

Serious: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Neurological events including Guillain‑Barré syndrome (rare). - Persistent high fever or severe systemic illness. - Seizures or convulsions (extremely rare).

Healthcare providers should assess individual health status before administering Havrix Junior and follow recommended precautions to ensure safe use.

- Verify the child is at least 12 months old before vaccination. - Defer vaccination in persons with known severe allergic reaction to any vaccine component, including aluminium hydroxide. - Postpone administration if the child has an acute moderate or severe illness with fever. - Consider a delayed schedule for children receiving immunoglobulin or blood products. - Counsel caregivers about expected mild reactions and when to seek medical attention. - Document any previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Junior may interact with other medical products; understanding these interactions helps optimize immunisation timing and safety.

Avoid: - Concurrent administration with live viral vaccines (e.g., measles‑mumps‑rubella) is generally avoided unless required by schedule. - Simultaneous receipt of immunoglobulin or blood products that contain anti‑hepatitis A antibodies may reduce vaccine effectiveness. - Avoid administration during febrile illness to prevent confusion of symptoms.

Use with caution: - Use with caution in children receiving immunosuppressive therapy, as response may be diminished. - Consider spacing from high‑dose steroids or chemotherapy to improve antibody development. - Monitor closely if the child is on antipyretic medication, as it may mask fever after vaccination. - Use with caution when the child is on antiplatelet agents, monitoring for injection‑site bleeding.